Comparative Pharmacology
Head-to-head clinical analysis: BRICANYL versus VOLMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRICANYL versus VOLMAX.
BRICANYL vs VOLMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; stimulates adenyl cyclase, increasing cyclic AMP, leading to bronchodilation.
Beta-2 adrenergic receptor agonist; stimulates adenylate cyclase, increasing cyclic AMP, leading to bronchodilation.
Subcutaneous: 0.25-0.5 mg every 1-2 hours as needed; Intravenous: 0.25-0.5 mg over 1 minute, may repeat every 1-2 hours; Inhalation (metered-dose inhaler): 2 inhalations (0.4 mg) every 6 hours; Nebulized: 2.5-5 mg every 6-8 hours.
Adults: 4-8 mg orally every 12 hours (sustained-release); maximum 16 mg every 12 hours.
None Documented
None Documented
3-4 hours (terminal); prolonged in renal impairment (up to 8-10 hours) and in elderly patients.
Terminal elimination half-life: 4-6 hours. Clinical context: requires twice-daily dosing in asthma.
Primarily renal (60-70% as unchanged drug and metabolites); fecal elimination accounts for a minor fraction (<5%).
Renal: 60-70% (unchanged and metabolites); fecal: 15-25%; biliary: <5%.
Category C
Category C
Beta-2 Agonist
Beta-2 Agonist